Vitamin E Supplementation Effect in Management of Calcium Oxalate Crystals

A randomized controlled trial (pre-post treatment) was conducted on 48 participants who met the inclusion criteria. The participants were selected from the OPD of Hussain Memorial Hospital in Lahore. They were divided into three groups, with each group consisting of 16 participants. The control group (T0) did not receive any treatment, while the treatment groups received different doses of Vitamin E supplementation. The first treatment group (T1) received 200mg of Vitamin E supplementation, and the second treatment group (T2) received 400mg of Vitamin E supplementation, both for a duration of 8 weeks. Data was collected at baseline and after the 8th week of the study, including blood samples for renal function tests (RFT), ultrasounds, and 24-hour urine samples for calcium and oxalate analysis.

Inclusion criteria

• Both male and female.
• Participants between the age of 20-50 years old.
• Presence of calcium oxalate crystals in urine and kidneys
• The size of the stones will range from 2 to 5 mm.

Exclusion criteria

• People having stones of Uric acid, struvite, Cystine.
• People having any other medical condition (End stage renal disease, Chronic Kidney disease, Kidney failure, and dialysis) .
• Subjects were excluded if they were taking any medications, which might affect vitamin E metabolism (such as Wrafrin, dalteparin sodium, enoxaparin sodium).
• Pregnant and lactating females.
• People having known allergies to Vitamin E supplementation (rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing).
• Participants enrolled in other studies or taking other nutraceutical preparations.